Haemonetics Co. (NYSE:HAE – Get Rating) EVP Anila Lingamneni sold 189 shares of the stock in a transaction on Monday, April 18th. The stock was sold at an average price of $56.55, for a total transaction of $10,687.95. Following the sale, the executive vice president now owns 14,013 shares of the company’s stock, valued at approximately $792,435.15. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
NYSE:HAE traded up $0.33 during mid-day trading on Tuesday, hitting $57.10. 457,529 shares of the company’s stock traded hands, compared to its average volume of 560,872. The company has a current ratio of 2.05, a quick ratio of 1.19 and a debt-to-equity ratio of 0.87. The business has a 50 day simple moving average of $57.84. Haemonetics Co. has a 1 year low of $43.50 and a 1 year high of $75.34. The stock has a market capitalization of $2.92 billion, a P/E ratio of 132.79, a PEG ratio of 2.06 and a beta of 0.30.
Haemonetics (NYSE:HAE – Get Rating) last posted its earnings results on Tuesday, February 8th. The medical instruments supplier reported $0.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.09. Haemonetics had a net margin of 2.37% and a return on equity of 17.33%. The firm had revenue of $259.77 million during the quarter, compared to the consensus estimate of $265.40 million. During the same period last year, the firm posted $0.81 EPS. The firm’s revenue for the quarter was up 8.1% on a year-over-year basis. Research analysts anticipate that Haemonetics Co. will post 2.53 earnings per share for the current year.
A number of analysts recently weighed in on HAE shares. Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Thursday, January 27th. StockNews.com assumed coverage on shares of Haemonetics in a research report on Thursday, March 31st. They set a “hold” rating for the company. Morgan Stanley cut their price objective on shares of Haemonetics from $68.00 to $60.00 and set an “equal weight” rating for the company in a research report on Friday, January 7th. Raymond James cut their price objective on shares of Haemonetics from $70.00 to $66.00 and set an “outperform” rating for the company in a research report on Wednesday, February 9th. Finally, Barrington Research restated an “outperform” rating on shares of Haemonetics in a research report on Wednesday, February 9th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $71.67.
About Haemonetics (Get Rating)
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
- Get a free copy of the StockNews.com research report on Haemonetics (HAE)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.